More articles about: Rogel Cancer Center

University of Michigan Health Rogel Cancer Center’s Cancer AnswerLine and infusion nurse, Christie Bryne, talks about multiple myeloma – a form of blood cancer.

The anti-cancer effect of the drug may help those with rare, hereditary cancer syndromes avoid surgeries by shrinking tumors via a daily oral dose.

New research suggests gastrointestinal diseases caused by immune system T cells could be mitigated by bolstering a common enzyme.

The algorithm FARDEEP offers a personalized approach to identify patients who better respond to regenerative therapies.

Focused on addressing health disparities, the Adolescent and Young Adult Oncology Program (AYA) at Michigan Medicine centers on more inclusive cancer care for this age group and dedicates its research to health equity for AYA cancer patients.

After surviving Hodgkin Lymphoma, Olivia Goff became a cancer nurse so she could share her experiences with other people dealing with cancer.

Multiple factors, ranging from fear of deportation to food insecurity, create a negative domino effect for the health of the MENA community.

Despite living with an adenoid cystic carcinoma, Celina Pitt finds joy in nightly dance parties with her husband.

The new approach blocks the interaction between cancer cells and immune receptors, showing promise in mice.

Dr. John Krauss, medical director of the multidisciplinary colorectal cancer clinic at the Rogel Cancer Center talks about how detection for colon and rectal cancer are similar while their treatment options can be different.

A urologic oncology fellow dedicates his career to debunking false notions about racial biology.

From early stage colon cancer to advanced metastatic disease, Jennifer Watson’s cancer journey illustrates the importance of advocating for your health and partnering with a care team you trust.

Facing a challenging diagnosis of metastatic urologic cancer, one of the state’s top communications professionals leans into her job, laughter and love.

The liver siphons critical immune cells to render immunotherapy ineffective; radiation to the liver may block this process.

Estrogen-lowering aromatase inhibitors are frequently prescribed to women with ovarian and uterine cancers. New research sheds light on how side effects impact these patients.